IGF-1 before and after GH peptides: what the lab number is telling you

The number you actually track when growth hormone signaling changes.

TL;DR

• IGF-1 (insulin-like growth factor 1) is the downstream marker clinicians track when prescribing growth hormone peptides like sermorelin or the CJC-1295/ipamorelin combination.
• It is more stable than measuring growth hormone directly because GH releases in short pulses and is hard to capture in a single blood draw.
• The goal is movement within the age- and sex-adjusted normal range — not a fixed target number.

What it is

IGF-1 stands for insulin-like growth factor 1 (in plain English: a protein the liver makes in response to growth hormone signals from the brain). Growth hormone (GH) tells the liver to release IGF-1, and most of GH’s downstream effects on tissue repair, muscle, and metabolism happen through IGF-1. When clinicians prescribe a GH peptide, they track IGF-1 because it gives a stable picture of how the system is responding (NIH StatPearls — IGF-1 reference, 2024).

How it works

Think of growth hormone like sparks from a fireworks fuse — bright flashes you cannot reliably catch with a snapshot camera. IGF-1 is the warm glow the fireworks leave on a hillside — easier to photograph and a better measure of how big the show actually was. The liver converts the GH signal into IGF-1 and releases it steadily into the bloodstream. A single morning blood draw catches the warm glow, not the sparks. That is why clinicians use it.

Who asks about it

People come to this topic when starting a growth hormone peptide protocol or when reviewing their first follow-up labs. They want to know what number to look at, what change to expect, and what the reference range means for them at their age. Many have a lab report in front of them and are trying to decode it.

What the research says

GH secretagogue therapy in published literature — sermorelin, CJC-1295, ipamorelin — is associated with measurable IGF-1 increases in physician-supervised protocols (NIH PMC therapeutic peptides review, 2018). The magnitude varies. Some patients see IGF-1 move from the low end of the age range toward the middle. Studied for its effects on body composition, sleep, and recovery, with IGF-1 as the primary biomarker. Distinguish: IGF-1 movement is a marker of system response — it is not by itself a clinical outcome.

What to know before considering it

Baseline IGF-1 is part of standard pre-peptide labs. Clinicians draw a follow-up roughly 6 to 12 weeks after starting, then periodically after. Reference ranges are age- and sex-adjusted — your lab report shows the band for your demographic. Generally well-tolerated in physician-supervised protocols. Very high IGF-1 has been linked to other health concerns in epidemiologic literature, which is why clinicians typically aim for the mid-range, not the ceiling. Individual response varies.

The Halftime POV

The IGF-1 number is one of the most useful lab markers in our category and one of the most often misread. We tell people what it actually reflects, what the change tends to look like, and why higher is not always better. Lab numbers are conversation starters with a licensed clinician — not score cards.

Related reading:

• IGF-1 lab: what it measures and how it differs from GH
• Why bloodwork is the foundation of every peptide protocol
• Sermorelin explained: the GHRH analog primer
• The classic peptide combination: CJC-1295 and ipamorelin

FAQ

Q: Why do clinicians track IGF-1 instead of growth hormone directly? A: Growth hormone is released in short pulses and is hard to measure reliably with a single blood draw. IGF-1 is more stable in the bloodstream and reflects average GH activity over the past day or two.

Q: What is a normal IGF-1 level? A: Normal ranges depend on age and sex. A 45-year-old man typically falls in a different range than a 25-year-old. Labs report age- and sex-adjusted reference intervals on the result page.

Q: How much should IGF-1 change on GH peptides? A: Movement is often modest — many patients see IGF-1 shift from the lower part of their age range toward the middle. Goal-setting is at clinician discretion, not a fixed target.

Q: Is high IGF-1 always good? A: No. Very high IGF-1 has been linked to other health concerns in epidemiologic literature. Clinicians typically aim for the mid-range of the age- and sex-adjusted reference interval, not the ceiling.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• NIH StatPearls — IGF-1 reference, 2024
• Therapeutic peptides: chemistry, manufacture, and clinical applications — NIH PMC, 2018

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.